SPOTLIGHT -
Dr. Kuykendall on the Potential for Momelotinib in Myelofibrosis
Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Read More
Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis
Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.
Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis
Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.
Dr. Kuykendall on the Impact of Ruxolitinib in Myeloproliferative Neoplasms
Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
